Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma

13 Feb 2025

Abstract excerpt

BACKGROUND: Glioblastoma (GB) is the most common and aggressive primary malignant brain tumor in adults. To date, no effective treatment has been reported for recurrent GB (rGB). Long noncoding RNA taurine upregulated gene 1 (TUG1), which is highly expressed in GB, resolves the formation of R-loops, thereby maintaining tumor growth. TUG1-targeting antisense oligonucleotide (ASO) (TUG1ASO) is a nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Glioma Diagnosis and Treatment
Share to RNA regulation and disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39948537
DOI: 10.1186/s12885-025-13623-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastomaPMID 39948537Read ↗

Development of Integrin α5β1-targeted PET/NIR imaging probes for glioblastoma intraoperative navigation and intracavity targeted radionuclide therapySemantic proximity Read ↗

Gene therapy in glioblastoma multiforme: Can it be a role changer?Semantic proximity Read ↗

Design and Biological Activity of a Novel Brain Penetrant Urea Compound Against GlioblastomaSemantic proximity Read ↗

Anlotinib plus Temozolomide for Recurrent Glioma: A Single-Center, Retrospective Study of 30 casesSemantic proximity Read ↗

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.Semantic proximity Read ↗

Integrated longitudinal analysis of glioblastomas with long-term relapse interval revealed upregulation of the Tumor Growth Factor β signaling pathway in the recurrent tumorSemantic proximity Read ↗

Differential DNA Methylation Patterns in Primary and Recurrent Glioblastoma : A Protumorigenic Role for the TEM8 GeneSemantic proximity Read ↗

Exploring the Potential Use of Non-coding RNAs as Possible Biomarkers for Glioma. Literature ReviewSemantic proximity Read ↗

Molecular targets in glioblastoma.Semantic proximity Read ↗

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Semantic proximity Read ↗

Overview of the Multifaceted Functions of LncRNA HOTAIR in GlioblastomaSemantic proximity Read ↗

Prognostic value of long non-coding RNA TUG1 in various tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.